Interview: Dr. Varun Sethi – VP Healthcare, DKSH Singapore &…
DKSH’s VP of Healthcare in Singapore and Malaysia, Dr. Varun Sethi deconstructs the essence of what it means to be a Market Expansion Services provider, while highlighting aspects of the…
As the leading Market Expansion Services Group with a focus on Asia, DKSH helps companies to grow their business in new or existing markets. We are a Swiss company headquartered in Zurich with 150 years of uninterrupted business presence in Asia.
We are one of the top 30 Swiss companies ranked by sales and employees with 770 business locations in 36 countries — 740 of them in Asia — and 28,300 specialized staff.
We provide our partners with sound expertise and on-the- ground logistics, based on a comprehensive network of unique size and depth. Our business activities are organized into four highly specialized Business Units that mirror our fields of expertise: Consumer Goods, Healthcare, Performance Materials and Technology.
With a strong Swiss heritage, DKSH has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.
Contact
24 Penjuru Rd, No. 03-02
609128 Singapore
+65 6471 1466
DKSH’s VP of Healthcare in Singapore and Malaysia, Dr. Varun Sethi deconstructs the essence of what it means to be a Market Expansion Services provider, while highlighting aspects of the…
Changi Airport Group’s Ching Kiat LIM reflects on a challenging 2020 for the airline industry, Changi’s longstanding excellence in pharmaceutical distribution, and how COVID-19 has pushed a greater embrace of…
Andrew Frye of medtech giant Baxter outlines his management strategy for the diverse APAC region, how growth was achieved in 2020 despite the drop in non-essential hospital visits and treatments…
Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading biopharmaceutical hubs and a magnet for top talent. Multitudes of biopharma and…
Singapore’s Institute of Mental Health offers a comprehensive range of psychiatric, rehabilitative, and psychotherapy services for the country’s population. CEO Associate Professor Daniel Fung discusses their work to transform mental…
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers…
Medtech industry veteran Sanjay Prabhakaran outlines the footprint and strategy of women’s health specialist Hologic in the dynamic Asia-Pacific region, how it leveraged its molecular diagnostics expertise to pivot towards…
Novo Nordisk Singapore’s Praful Chakkarwar explains how he leverages his experience in a range of geographies in his current role, how COVID-19 has helped facilitate the affiliate’s digital transformation, the…
Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders explains the challenges of working in…
ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead…
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other…
Dr Choong May Ling, Mimi, CEO of Singapore’s Health Sciences Authority (HSA), one of the leading regulatory bodies in the Asia-Pacific region, outlines the impact of Singapore’s status as a…
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems…
See our Cookie Privacy Policy Here
